We provide the infrastructure, technologies, and expertise required to execute early phase patient studies worldwide.
Today, there’s an increased interest in having patient safety and efficacy data available as early as possible during the clinical pharmacology program. PRA’s innovative Early Patient Solutions (EPS) provides a lean proof-of-concept model. This model is designed to evaluate clinical endpoints and biomarkers within a smaller sample size of patients, which provides earlier data for go/no go decisions.
Early patient trials require a special approach due to:
- Multi-site setup for patient access
- Patient confinement for safety monitoring
- Intensive procedures and PK sampling
- Urgent timelines for data and results
- Multi-stage dose escalation studies and adaptive protocols
- A cost-effective approach
EPS provides an end-to-end solution perfectly suited for these trials. Leveraging PRA’s range of specialized therapeutic, operational, and drug development expertise, along with global resources, we develop customized solutions to help clients achieve their key milestones.
Drug developers are making the critical decision of whether or not to proceed. EPS offers a solution with reduced time and cost from the drug development timeline.
State-of-the-art Clinical Facilities
We provide end-to-end bioanalytical support from Pre-clinical to Phase IV studies. At PRA, our laboratories are managed, staffed, and supported by…
Bioanalysis, Biomarker and Flow Cytometry Assay List
Bioanalysis, Biomarker and Flow Cytometry Assay List. PRA Laboratories—Solutions for Drug Development. Behind every sample waiting to be analyzed,…
Phase I healthy volunteer studies play a vital role in clinical research by providing researchers with the knowledge they need to make educated…
Early Phase Studies in Patients
PRA Health Sciences’ Early Development Services (EDS) team of dedicated experts understands that obtaining patient safety and efficacy data early in…
Human Abuse Potential and Liability (HAP)
We’ve successfully completed more Human Abuse Potential and Liability (HAP/HAL) protocols & published more HAP studies than any other CRO.